Genetically Engineered Artificial Exosome-Constructed Hydrogel for Ovarian Cancer Therapy.

Owing to the insidious onset of ovarian cancer, most patients are in the advanced stage with extensive peritoneal metastasis when they are diagnosed. Treatment of peritoneal metastasis from advanced ovarian cancer remains a significant challenge. Inspired by the massive macrophages in the peritoneal environment, here, we reported an artificial exosome-based peritoneal-localized hydrogel to domesticate peritoneal macrophages as the therapeutic target for realizing potent ovarian cancer therapy, where artificial exosomes derived from genetically sialic-acid-binding Ig-like lectin 10 (Siglec-10)-engineered M1-type macrophages were chemically designed as gelator. Upon triggering immunogenicity with X-ray radiation, our hydrogel encapsulating efferocytosis inhibitor MRX-2843 enabled a cascade regulation to orchestrate polarization, efferocytosis, and phagocytosis of peritoneal macrophages for realizing robust phagocytosis of tumor cells and powerful antigen presentation, offering a potent approach for ovarian cancer therapy via bridging the innate effector function of macrophages with their adaptive immune response. Moreover, our hydrogel is also applicable for potent treatment of inherent CD24-overexpressed triple-negative breast cancer, providing an emerging therapeutic regimen for the most lethal malignancies in women.

[1]  Y. Luan,et al.  Radiotherapy-Mediated Redox Homeostasis-Controllable Nanomedicine for Enhanced Ferroptosis Sensitivity in Tumor Therapy. , 2023, Acta biomaterialia.

[2]  Yeonseok Chung,et al.  Nanovesicle‐Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects , 2021, Advanced materials.

[3]  Chun Gwon Park,et al.  T‐Cell‐Derived Nanovesicles for Cancer Immunotherapy , 2021, Advanced materials.

[4]  G. Testa,et al.  Exploiting epigenetic dependencies in ovarian cancer therapy , 2021, International journal of cancer.

[5]  K. Zen,et al.  Intratumoral SIRPα-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy , 2021, Nature Communications.

[6]  Xiaoquan Lu,et al.  Exosome‐Coated Zeolitic Imidazolate Framework Nanoparticles for Intracellular Detection of ATP † , 2021 .

[7]  Z. Modrušan,et al.  Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. , 2020, Immunity.

[8]  Rachel E. Brewer,et al.  CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy , 2019, Nature.

[9]  Zu-hua Gao,et al.  High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints , 2019, International journal of molecular sciences.

[10]  S. Trefely,et al.  Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated ‘don’t eat me signal’. , 2018, Nature Immunology.

[11]  F. Yull,et al.  Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy , 2018, Cancers.

[12]  S. Nagata.  Apoptosis and Clearance of Apoptotic Cells. , 2018, Annual review of immunology.

[13]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[14]  S. Demaria,et al.  In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. , 2015, Vaccine.

[15]  Jaime Prat,et al.  FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication , 2015, Journal of gynecologic oncology.

[16]  K. Davies,et al.  The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer , 2014, Nature Reviews Cancer.

[17]  Diana Boraschi,et al.  From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation , 2014, Front. Immunol..

[18]  F. Finkernagel,et al.  Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse , 2013, International journal of cancer.

[19]  Thomas A. Wynn,et al.  Macrophage biology in development, homeostasis and disease , 2013, Nature.

[20]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[21]  M. Fehlings,et al.  CD8− Dendritic Cells and Macrophages Cross-Present Poly(D,L-lactate-co-glycolate) Acid Microsphere-Encapsulated Antigen In Vivo , 2011, The Journal of Immunology.

[22]  Yasunobu Miyake,et al.  CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. , 2011, Immunity.

[23]  H. Katabuchi,et al.  Involvement of M2‐polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation , 2010, Cancer science.

[24]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[25]  Leonore A. Herzenberg,et al.  Two physically, functionally, and developmentally distinct peritoneal macrophage subsets , 2010, Proceedings of the National Academy of Sciences.

[26]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[27]  H. Katabuchi,et al.  Detection of M2 macrophages and colony‐stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors , 2009, Pathology international.